Shots:
- Health Canada has granted NOC to Bevqolva (bevacizumab), a biosimilar version of Genentech’s Avastin
- Bevacizumab, a humanized mAb, inhibits angiogenesis by blocking VEGF-A to slow tumor vascular growth in cancers like colorectal and lung. Marketed by Roche/Genentech as Avastin, it is available in 100 mg and 400 mg formulations
- In 2025, Bevqolva received MHRA approval and was launched in the UK. It is under CHMP review with the EMA, while CuraTeQ Biologics also has two biosimilar applications under review by Health Canada
Ref: CuraTeQ| Image: CuraTeQ|Press Release
Related News: CuraTeQ Reports P-III Trial Data on BP11 (Biosimilar, Xolair) in Chronic Spontaneous Urticaria
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
